Loading
A phase 2 trial of Ficerafusp alfa, Pembrolizumab in head and neck squamous cell carcinoma, run by Bicara Therapeutics, now recruiting.
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC is a phase 2 interventional study registered as NCT07807163 by Bicara Therapeutics, with 160 participants planned, started 2026-09 and due to reach its primary completion in 2028-03. Interventions recorded: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®). Conditions listed: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Bicara Therapeutics, Ficerafusp alfa, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, Head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Ficerafusp alfa, Head and neck squamous cell carcinoma, Pembrolizumab.
Shares Bispecific antibodies, Head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.